![](https://www.worldpharmatoday.com/images/nBanners/Docuvera-728x90.jpeg")
It is well worth noting that the last few years have seen a rapid period when it comes to technological adoption in the life sciences sector, mostly pushed by the pandemic. As the industry moves on, it is bent on finding new approaches to applying technology so as to enhance clinical research, broaden the trials to wider, more varied population sets, and also enhance drug safety.
Listed are some key areas to look for in the pharmaceutical and clinical research spectrum as one approaches 2024:
Integration with real-world data will be more active
Clinical research blended with real-world data- RWD goes on to offer deeper insights into the natural history of diseases as well as the performance of healthcare interventions in terms of real-world settings. Such real-world data sources, which include patient-reported outcomes, data from wearable devices, insurance claims data, along with detailed patient histories that were found in electronic health records- EHRs can go on to provide a more filtered understanding of treatments when it comes to real-life settings. This information will become imperative in elevating clinical trial execution, coming up with drug safety and efficacy evidence, as well as supporting drug reimbursement strategies.
Customized medicine will be a focus
By making use of advanced analytics, machine learning, and computational power to glean insights from the information, clinical research will go on to focus on aspects to come up with personalized therapies when it comes to individuals’ precise conditions and not just general diseases. One can anticipate seeing a major shift towards taking up the patient’s voice and also ensuring that every stage in drug development gets informed by the nuanced, real-life, diverse patient populations. Advancements in technology, especially generative AI as well as high-performance cloud computing, can now help one evaluate vast and varied datasets with a great amount of speed and precision. Along with RWD, these techs can go on to provide a better understanding of treatments in real-life scenarios. This integration will help the sector customize therapies more effectively, better engage patients across the process, and bridge the gap in clinical research and clinical care.
The cloud, along with AI adoption, will help narrow the gap between clinical research as well as clinical care
At present, clinical research happens to be based on small snippets of health data, as several critical elements of patient clinical care data are inaccessible as well as siloed. The sector is almost there, to the point where cloud computing, technology, data integration, and clinical care research can all be aspects of the same spectrum. Cloud technology is aiding in bridging the gap toward wider access to connected as well as stronger data sets. As AI helps with quicker analysis as well as faster insights, clinical research will go on to become more accessible, affordable, and accurate because the data will be based on information that looks to be more complete.
For instance, as new customized treatments along with therapies come to the market and in the future, patients as well as providers need to have precise information about their safety along with possible adverse reactions. Automation and AI can help with predictive signal detection, in which systems can identify potential issues prior to they take place and help eradicate tedious and repetitive tasks as well as errors. One can witness continued investment when it comes to AI and large language models- LLMs so as to improve operational efficiencies in terms of pharmacovigilance processes. Along with the real-world data, these steps can greatly reduce the time as well as effort required in terms of analysing the data and pinpointing the potential risk factors as far as the new drugs are concerned. This will enable in early identification in terms of adverse events and also enhance drug safety tracking.
As the advantages of AI go on to impact the entire lifecycle of clinical trials, one will witness the burden on patients decrease as they will have more feasible clinical trials to opt from and more control over how they go on to participate. This will thereby cut the time it takes in terms of drugs to hit the market as well as reduce the overall costs associated when it comes to clinical trials.
Generative AI will make its statement
Particularly generative AI will go on to start to transform every phase when it comes to drug development, pushing efficiencies throughout discovery, clinical trials, along with safety by way of automation, optimization, along with advanced insights. LLMs will elevate the understanding of biology as well as molecular screening, enhancing the speed and quality of early preclinical drug discovery pipelines that can aid in unlocking new therapies. Generative AI can also go on to play a significant role in clinical trials by taking into account diverse patient populations, integrating numerous data sets such as genomics, EHRs, and RWD so as to increase patient recruitment and trial success rates, and optimizing trial designs. One may even witness the generative AI that will enable one to get closer to making complete digital protocols a reality in the times to come.
Decentralized as well as hybrid trials will become normalized
It is well to be noted that the pandemic accelerated immensely the embrace of decentralized clinical trials- DCT. Things such as connected devices along with wearables have gone on to create an environment where DCTs have gone on to become as well as continue to evolve as a feasible option so as to collect the needed information. This will lessen the barriers to entry, broaden access to trials, and better the patient convenience.
There will also be a focus on patient optionality so as to create wider access to, as well as diversity in, clinical trials
Next year will see a more precise effort by trial providers so as to make it seamless to connect patients as well as providers with clinical trials. In the case of doctors and patients, going ahead with enabling access to varied health systems that share de-identified data so as to fuel research and connect patients with trials that are viable and will help to speed up the discovery, development, as well as deployment of groundbreaking insights along with therapies. Community-based settings, like commercial pharmacies, small community hospitals, as well as pharmacies at local grocers, will go on to offer more trial sites and come up with broader and more diverse access for patients across socio-economic backgrounds as well as geographies.
There is indeed no shred of doubt that cloud computing, automation, as well as AI will go on to reshape the life sciences sector, along with the approach to clinical trials moving forward. The effect these technologies have on shifting all facets of the industry will be felt throughout all aspects of clinical research, from study start-up to customized care to drug safety. The companies that go on to leverage these as well as other technologies the most aptly are the ones who will bring viable, safer treatments to the market much faster.
